Nanoencapsulated chitosan nanoparticles in emulsion-based oral delivery system: In vitro and in vivo evaluation of insulin loaded formulation

2016 ◽  
Vol 36 ◽  
pp. 161-167 ◽  
Author(s):  
Gülşah Erel ◽  
Mustafa Kotmakçı ◽  
Hasan Akbaba ◽  
Sumru Sözer Karadağlı ◽  
Ayşe Gülten Kantarcı
Biomaterials ◽  
2006 ◽  
Vol 27 (23) ◽  
pp. 4250-4255 ◽  
Author(s):  
Florian Föger ◽  
Thierry Schmitz ◽  
Andreas Bernkop-Schnürch

2011 ◽  
Vol 420 (1) ◽  
pp. 172-179 ◽  
Author(s):  
Liting Guo ◽  
Erli Ma ◽  
Haiwei Zhao ◽  
Yingfang Long ◽  
Changxue Zheng ◽  
...  

2012 ◽  
Vol 80 (1) ◽  
pp. 95-102 ◽  
Author(s):  
Javed Iqbal ◽  
Gul Shahnaz ◽  
Glen Perera ◽  
Fabian Hintzen ◽  
Federica Sarti ◽  
...  

Author(s):  
Venu Madhav K ◽  
Somnath De ◽  
Chandra Shekar Bonagiri ◽  
Sridhar Babu Gummadi

Fenofibrate (FN) is used in the treatment of hypercholesterolemia. It shows poor dissolution and poor oral bioavailability after oral administration due to high liphophilicity and low aqueous solubility. Hence, solid dispersions (SDs) of FN (FN-SDs) were develop that might enhance the dissolution and subsequently oral bioavailability. FN-SDs were prepared by solvent casting method using different carriers (PEG 4000, PEG 6000, β cyclodextrin and HP β cyclodextrin) in different proportions (0.25%, 0.5%, 0.75% and 1% w/v). FN-SDs were evaluated solubility, assay and in vitro release studies for the optimization of SD formulation. Differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD) and scanning electron microscopy (SEM) analysis was performed for crystalline and morphology analysis, respectively. Further, optimized FN-SD formulation evaluated for pharmacokinetic performance in Wistar rats, in vivo in comparison with FN suspension.  From the results, FN-SD3 and FN-SD6 have showed 102.9 ±1.3% and 105.5±3.1% drug release, respectively in 2 h. DSC and PXRD studies revealed that conversion of crystalline to amorphous nature of FN from FT-SD formulation. SEM studies revealed the change in the orientation of FN when incorporated in SDs. The oral bioavailability FN-SD3 and FN-SD6 formulations exhibited 2.5-folds and 3.1-folds improvement when compared to FN suspension as control. Overall, SD of FN could be considered as an alternative dosage form for the enhancement of oral delivery of poorly water-soluble FN.


2009 ◽  
Vol 6 (2) ◽  
pp. 151-158 ◽  
Author(s):  
N. Dobaria ◽  
R. Mashru ◽  
A. Badhan ◽  
A. Thakkar

Sign in / Sign up

Export Citation Format

Share Document